Prelude Therapeutics Inc
General ticker "PRLD" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $53.3M
Prelude Therapeutics Inc does not follow the US Stock Market performance with the rate: -18.1%.
Estimated limits based on current volatility of 14.0%: low 1.01$, high 1.34$
Factors to consider:
- Current price 46.8% below estimated low
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [2.33$, 6.62$]
- 2024-12-30 to 2025-12-30 estimated range: [2.42$, 6.69$]
Financial Metrics affecting the PRLD estimates:
- Negative: Non-GAAP EPS, $ of -2.04 <= 0.10
- Negative: Operating profit margin, % of -100 <= 1.03
- Negative: Operating cash flow per share per price, % of -32.94 <= 2.35
- Positive: Inventory ratio change, % of 0 <= 0
- Negative: negative Net income
Short-term PRLD quotes
Long-term PRLD plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $113.73MM | $123.54MM | $132.28MM |
| Operating Income | $-113.73MM | $-123.54MM | $-132.28MM |
| Non-Operating Income | $2.04MM | $8.10MM | $10.45MM |
| R&D Expense | $86.78MM | $92.89MM | $103.39MM |
| Income(Loss) | $-111.69MM | $-115.44MM | $-121.83MM |
| Profit(Loss) | $-111.69MM | $-115.44MM | $-121.83MM |
| Stockholders Equity | $285.90MM | $195.44MM | $237.09MM |
| Assets | $305.10MM | $220.50MM | $277.67MM |
| Operating Cash Flow | $-83.53MM | $-83.73MM | $-107.06MM |
| Capital expenditure | $2.32MM | $3.02MM | $3.51MM |
| Investing Cash Flow | $-263.80MM | $81.69MM | $-34.65MM |
| Financing Cash Flow | $164.90MM | $0.81MM | $136.40MM |
| Earnings Per Share* | $-2.33 | $-2.27 | $-2.02 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.